Home Cart Sign in  
Chemical Structure| 1018899-04-1 Chemical Structure| 1018899-04-1

Structure of Sotagliflozin
CAS No.: 1018899-04-1

Chemical Structure| 1018899-04-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

LX4211 is an inhibitor of SGLT2 and SGLT1 with antidiabetic activity.

Synonyms: LX-4211; LP-802034

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Sotagliflozin

CAS No. :1018899-04-1
Formula : C21H25ClO5S
M.W : 424.94
SMILES Code : O[C@H]1[C@H](C2=CC=C(Cl)C(CC3=CC=C(OCC)C=C3)=C2)O[C@H](SC)[C@@H](O)[C@@H]1O
Synonyms :
LX-4211; LP-802034
MDL No. :MFCD22493506
InChI Key :QKDRXGFQVGOQKS-CRSSMBPESA-N
Pubchem ID :24831714

Safety of Sotagliflozin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • SGLT1

    SGLT1, IC50:36 nM

  • SGLT2

    SGLT2, IC50:1.8 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
C2C12 skeletal muscle cells 5-20 μM 24 hours Sotagliflozin pretreatment significantly enhanced the expression levels of angiogenic factors HIF-1α, VEGF-A, and PDGF-BB in HG-treated C2C12 cells under hypoxia, as well as the secreted amounts of VEGF-A and PDGF-BB in the medium. PMC9525294

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
rats ZSF-1 obese rats (a metabolic syndrome-related HFpEF model) Oral feeding 30 mg/kg/d Once daily for 6 weeks Sotagliflozin ameliorated LA enlargement in HFpEF rats and reduced the magnitude of spontaneous Ca2+ release events in LA cardiomyocytes. PMC7792219
Rabbits CF rabbit model Oral 15 mg/kg Once daily, until the experiment endpoint (150 days or older) To evaluate the systemic effects of Sotagliflozin on lifespan, appetite, body weight, liver function, etc., in CF rabbits. Results showed that Sotagliflozin significantly extended the lifespan of CF rabbits, improved appetite and body weight, and alleviated liver fibrosis and NASH-like phenotypes. PMC10972622
Mice Diabetic hindlimb ischemia (HLI) model Intramuscular injection 10 mg/kg Once every 3 days for 3 weeks Intramuscular injection of sotagliflozin effectively promoted the formation of functional blood vessels, leading to significant recovery of blood perfusion in diabetic HLI mice. PMC9525294
C57BL/6J mice Cardiac pressure overload model Oral gavage 10 mg/kg body weight Once daily for 7 weeks Sotagliflozin attenuated TAC-induced cardiac hypertrophy and fibrosis in normal diet mice but did not show cardioprotective effects in high-fat diet mice. PMC8490778

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT06433050 Hypertrophic Cardiomyopathy Wi... More >>thout Obstruction Less << EARLY_PHASE1 RECRUITING 2025-06-27 University of Pennsylvania, Ph... More >>iladelphia, Pennsylvania, 19104, United States Less <<
NCT06510894 Cardiac Sarcoidosis RECRUITING 2027-12-31 University of Pennsylvania, Ph... More >>iladelphia, Pennsylvania, 19104, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.35mL

0.47mL

0.24mL

11.77mL

2.35mL

1.18mL

23.53mL

4.71mL

2.35mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories